346 Pre-clinical characterization of AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A11:01 that is multi-armored to increase epitope sensitivity
BackgroundKRAS is one of the most mutated genes in human cancer, with the G12D mutation having the highest frequency, occurring in 28% and 12% of pancreatic cancer (PDAC) and colorectal cancer (CRC), respectively. KRAS G12D-containing peptides are presented by the common HLA allele HLA-A*11:01, maki...
Saved in:
| Published in: | Journal for immunotherapy of cancer Vol. 13; no. Suppl 2; p. A396 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BMJ Publishing Group LTD
01.11.2025
|
| Subjects: | |
| ISSN: | 2051-1426 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | BackgroundKRAS is one of the most mutated genes in human cancer, with the G12D mutation having the highest frequency, occurring in 28% and 12% of pancreatic cancer (PDAC) and colorectal cancer (CRC), respectively. KRAS G12D-containing peptides are presented by the common HLA allele HLA-A*11:01, making this cancer neoantigen a highly attractive target for the development of adoptive TCR-T cell therapy. However, the levels of cancer neoantigen presentation are typically low and combined with the immunosuppressive tumor microenvironment this compromises the activation and reactivity of TCR-engineered T cells, posing a major hurdle for these cells to eradicate tumor lesions.MethodsTo establish a TCR-T cell therapy intended for the treatment of solid cancers, including PDAC and CRC, we developed AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A*11:01. To improve the reactivity of AZD0240 to the KRAS-G12D neoantigen, we developed a novel multi-armoring strategy, involving the combined disruption of a key negative regulator of T cell function and the introduction of a positive enhancement of TCR signaling.ResultsEmploying this multi-armoring strategy, we observed enhanced cytokine production in response to low levels of exogenously loaded KRAS-G12D peptide, as well as to HLA-A*11:01+ tumor cells that express the KRAS-G12D mutation. Moreover, assessment of the in vitro and in vivo proliferative and cytotoxic capacity revealed that the AZD0240 armoring strategy profoundly increased both the clonal expansion and the anti-tumor efficacy of TCR-engineered T cells. Notably, the armored AZD0240 T cells were unable to respond to the KRAS G12 wild-type epitope, and no signs of increased TCR cross- or allo-reactivity, or malignant transformation were detected, derisking the clinical use of this armoring strategy.ConclusionsTaken together, AZD0240 is a KRAS-G12D/HLA-A*11:01-targeted TCR-T cell therapy that employs a novel multi-armoring strategy and is currently in preparation for clinical testing, with encouraging signs of pre-clinical efficacy and safety. |
|---|---|
| AbstractList | BackgroundKRAS is one of the most mutated genes in human cancer, with the G12D mutation having the highest frequency, occurring in 28% and 12% of pancreatic cancer (PDAC) and colorectal cancer (CRC), respectively. KRAS G12D-containing peptides are presented by the common HLA allele HLA-A*11:01, making this cancer neoantigen a highly attractive target for the development of adoptive TCR-T cell therapy. However, the levels of cancer neoantigen presentation are typically low and combined with the immunosuppressive tumor microenvironment this compromises the activation and reactivity of TCR-engineered T cells, posing a major hurdle for these cells to eradicate tumor lesions.MethodsTo establish a TCR-T cell therapy intended for the treatment of solid cancers, including PDAC and CRC, we developed AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A*11:01. To improve the reactivity of AZD0240 to the KRAS-G12D neoantigen, we developed a novel multi-armoring strategy, involving the combined disruption of a key negative regulator of T cell function and the introduction of a positive enhancement of TCR signaling.ResultsEmploying this multi-armoring strategy, we observed enhanced cytokine production in response to low levels of exogenously loaded KRAS-G12D peptide, as well as to HLA-A*11:01+ tumor cells that express the KRAS-G12D mutation. Moreover, assessment of the in vitro and in vivo proliferative and cytotoxic capacity revealed that the AZD0240 armoring strategy profoundly increased both the clonal expansion and the anti-tumor efficacy of TCR-engineered T cells. Notably, the armored AZD0240 T cells were unable to respond to the KRAS G12 wild-type epitope, and no signs of increased TCR cross- or allo-reactivity, or malignant transformation were detected, derisking the clinical use of this armoring strategy.ConclusionsTaken together, AZD0240 is a KRAS-G12D/HLA-A*11:01-targeted TCR-T cell therapy that employs a novel multi-armoring strategy and is currently in preparation for clinical testing, with encouraging signs of pre-clinical efficacy and safety. |
| Author | Kok Lianne Heijst Jeroen van Perez, Arianne Bendle Gavin Eshuis Sander Linnemann Carsten Ma, Jennifer Cobbold, Mark Schumacher, Ton Grace Sun Ka Hei Mojadidi Michelle Kroon, Paula Tubb, Vanessa Hall, Elizabeth Kong Xiangjun |
| Author_xml | – sequence: 1 fullname: Kok Lianne – sequence: 2 fullname: Eshuis Sander – sequence: 3 fullname: Kong Xiangjun – sequence: 4 givenname: Jennifer surname: Ma fullname: Ma, Jennifer – sequence: 5 fullname: Mojadidi Michelle – sequence: 6 givenname: Elizabeth surname: Hall fullname: Hall, Elizabeth – sequence: 7 fullname: Grace Sun Ka Hei – sequence: 8 givenname: Paula surname: Kroon fullname: Kroon, Paula – sequence: 9 givenname: Vanessa surname: Tubb fullname: Tubb, Vanessa – sequence: 10 givenname: Ton surname: Schumacher fullname: Schumacher, Ton – sequence: 11 givenname: Arianne surname: Perez fullname: Perez, Arianne – sequence: 12 fullname: Linnemann Carsten – sequence: 13 givenname: Mark surname: Cobbold fullname: Cobbold, Mark – sequence: 14 fullname: Heijst Jeroen van – sequence: 15 fullname: Bendle Gavin |
| BookMark | eNotUM1O4zAYtFaLtCzwDPtJe8Xlc9wkLrco_FVUArU57QU57pfiKtjFdpDgxIVX4oH2SQiC04xGoxnN_GY_nXfE2B-BEyFkcbK1yfAMs5yv5k39SSYop8UPtp9hLriYZsUvdhTjFhEFSqmU2mfvo-P_69ttIG5666zRPZh7HbRJFOyLTtY78B1U_84wm-IxaKiX89XtkpPbWEcUaA16SL73Gz9EaOolb8BQ38Mu-PVgEiQdNpSs28D1slrxS5GdnVwtKl4JcYoC0r1OYCM8DH2yXIcH_xmZPFhnAulIQDub_I4gkos22Sebng_ZXqf7SEffeMCai_OmvuKLm8t5XS34riwLXq6xnApJssWuRYN6XLBuZ7Id_zKdNuVMksI275RCU8xyklq1ZalJdKNQGnnA_n7FjlseB4rpbuuH4MbGO5kVSsqZUrn8AG6XdjA |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | K9. |
| DOI | 10.1136/jitc-2025-SITC2025.0346 |
| DatabaseName | ProQuest Health & Medical Complete (Alumni) |
| DatabaseTitle | ProQuest Health & Medical Complete (Alumni) |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| EndPage | A396 |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ADBBV ADRAZ AFFHD AFKRA AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR K9. KQ8 M1P M~E OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RBZ RMJ RPM RSV SOJ UKHRP |
| ID | FETCH-LOGICAL-p776-7d07413e3b0fb0c0a240db93b113cfac793e80b5f880c695e3a8b77ae1f80c7c3 |
| IngestDate | Tue Nov 04 14:28:15 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 2 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-p776-7d07413e3b0fb0c0a240db93b113cfac793e80b5f880c695e3a8b77ae1f80c7c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| OpenAccessLink | https://jitc.bmj.com/content/13/Suppl_2/A396.full.pdf |
| PQID | 3268339885 |
| PQPubID | 2040222 |
| ParticipantIDs | proquest_journals_3268339885 |
| PublicationCentury | 2000 |
| PublicationDate | 20251101 |
| PublicationDateYYYYMMDD | 2025-11-01 |
| PublicationDate_xml | – month: 11 year: 2025 text: 20251101 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationYear | 2025 |
| Publisher | BMJ Publishing Group LTD |
| Publisher_xml | – name: BMJ Publishing Group LTD |
| SSID | ssj0001033888 |
| Score | 2.3079433 |
| Snippet | BackgroundKRAS is one of the most mutated genes in human cancer, with the G12D mutation having the highest frequency, occurring in 28% and 12% of pancreatic... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | A396 |
| SubjectTerms | Cancer CRISPR Lymphocytes |
| Title | 346 Pre-clinical characterization of AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A11:01 that is multi-armored to increase epitope sensitivity |
| URI | https://www.proquest.com/docview/3268339885 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral Open Access_ databaseCode: RBZ dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.biomedcentral.com/search/ omitProxy: false ssIdentifier: ssj0001033888 providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals databaseCode: DOA dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.doaj.org/ omitProxy: false ssIdentifier: ssj0001033888 providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources databaseCode: M~E dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://road.issn.org omitProxy: false ssIdentifier: ssj0001033888 providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection databaseCode: 7X7 dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://search.proquest.com/healthcomplete omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central databaseCode: BENPR dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.proquest.com/central omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database databaseCode: PIMPY dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: http://search.proquest.com/publiccontent omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Pj9JAFJ4sizFezPor_ljJHIyXOm7LtJ2ptwqsIAtpgAN6IdMyVVZTkMJm48mL_5J_kH-Jb4ahVFmNHrw0ZSh00vf1zZuX770PoSfUE6lkKSeu6wbE9RwK75xUvfGmbqqaw0gRa7EJ1u_z8TiIDipH21qYi48sy_jlZbD4r6aGMTC2Kp39B3MXfwoDcA5GhyOYHY5_ZXjq-obBwL1oKUlR-5gUvZk_F3Fi-Lap2o9pDqfVGHSG0YBI06IQQlGx1vK2iiY7agzIyFJ5fsXpUl1irQ2LXOUauoNwSF459SZMu30WkhAcJA1tB8JasVKa6Zq3SMRS0XqnKt6dZSpczaUlF-BTFtLKFZN-I2VxVcCs2JAzVctiKsY0MSBRkC3Yxd35B-sM0L4jCrTy92u4-VBX8OwugwmP4bp35-vizeiJMtWnnAqpe6YmsMj39V7vJe8KyRGpfWodfBBx3E2RfrEA0BLQtZiqVS_59JAGfik-2H7cX3u0OM75bJUQPblhZ9RQJ89t6l7R7bsdDidR83Ry1ul3ny4-ESWEpggDRhWmgqp15gXgqKtRpxe92SUObUo554arCDc9-c0t96ILHTKNjtBNYzocbjB6Cx3I7Da63jNsjjvoG_z8-5evZZDiX0GK5yk2IH2GBd6DKN5BFGuIYgVRbCCKC4jiAqInBqAvbAcreOJZjn-CJ17N8Rae2MATl-B5F41OW6NGmxgdEbJgzCdsqsJmKmlsp7Gd2AJmPI0DGsPDS1KRwAoluR17KSxliR94kgoeMyakk8IAS-g9dJjNM3kfYZf5jrC9OEjB4UhvymHDI3hSh12_7cTcf4COt498YlxCPoENEqc04Nx7-OevH6EbO1Qfo8PVci0fo2vJxWqWL2uowsashqovW_1oUNO5o5rBxg_jd7ar |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=346%E2%80%85Pre-clinical+characterization+of+AZD0240%2C+a+CRISPR-engineered+autologous+TCR-T+cell+product+targeting+KRAS-G12D%2FHLA-A11%3A01+that+is+multi-armored+to+increase+epitope+sensitivity&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Kok+Lianne&rft.au=Eshuis+Sander&rft.au=Kong+Xiangjun&rft.au=Ma%2C+Jennifer&rft.date=2025-11-01&rft.pub=BMJ+Publishing+Group+LTD&rft.eissn=2051-1426&rft.volume=13&rft.issue=Suppl+2&rft.spage=A396&rft.epage=A396&rft_id=info:doi/10.1136%2Fjitc-2025-SITC2025.0346&rft.externalDBID=HAS_PDF_LINK |